key: cord-0739518-e4ern5ke
authors: Tesarik, Jan
title: Melatonin: a fertility-friendly anti-coronavirus agent
date: 2020-09-08
journal: Reprod Biomed Online
DOI: 10.1016/j.rbmo.2020.09.004
sha: 6a295934d9c2f24976c7090897063d4e0973060f
doc_id: 739518
cord_uid: e4ern5ke

nan

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo editing, typesetting, and review of the resulting proof before it is published in its final form. Please note that during this process changes will be made and errors may be discovered which could affect the content. Correspondence or other submissions concerning this article should await its publication online as a corrected proof or following inclusion in an issue of the journal.

I read with interest the article by Li et al. (2020) expressing concern about potential long-term effects of coronavirus disease-19 (COVID-19) on reproductive health. The authors focused on effects caused by the virus itself, antiviral treatments, chemical disinfectants, and panic psychology during the COVID-19 outbreak. In this letter, I would like to draw the attention of scientists and clinicians to melatonin, which combines effects against most of these risk factors. Melatonin may be able to prevent the development of COVID-19 symptoms, decrease the severity of already present symptoms, reduce stress, and attenuate the immunopathology of COVID-19 after the active phase of the infection (Shneider et al., 2020) . Despite ample circumstantial evidence, the efficacy of melatonin as a therapeutic agent against COVID-19 has not yet been proven by randomized controlled trials (RCT). However, RCT designed to test melatonin in this indication may be ethically questionable. In fact, an equipose-genuine doubt about whether one course of action is better than another -one of the ethical requirements for building an RCT -is not met in this case. On the contrary, evidence suggests that patients in the melatonin arm of the study are more likely to benefit from enrolment than patients in the other arm. Thus, I suggest the use melatonin without RCT, as recently recommended by the World Health Organization for Ebola disease (Adebamowo et al., 2014) . Moreover, melatonin lacks toxicity and has other beneficial effects for human health, including the prevention of cancer (Li et al., 2017) .

Randomised controlled trials for Ebola: practical and ethical issues

Potential risks of SARS-Cov-2 infection on reproductive health

Can melatonin reduce the severity of COVID-19 pandemic?